文献速递功能神经外科

显微血管减压术与伽玛刀放射外科治疗三叉神经痛的成本效果分析比较

Comparing Microvascular Decompression with Gamma Knife Radiosurgery for Trigeminal Neuralgia. A Cost-Effectiveness Analysis.
PubMed 文献 · World Neurosurg · 2019-01-17

本研究建立美国卫生体系Markov成本效果模型,在患者终生时间跨度内比较显微血管减压术(MVD)与伽玛刀放射外科(GKRS)治疗三叉神经痛的成本效果。基础病例中MVD相比GKRS的增量成本效果比(ICER)为每获得1个质量调整生命年(QALY)12,154美元;概率敏感性分析显示MVD在70%的模型迭代中具有成本效果。作者认为在两种手术均医学可行的患者中,MVD是最具成本效果的策略,主要因其耐久性更佳。

要点

  • 基础病例MVD相比GKRS的ICER为每QALY 12,154美元,低于50,000美元/QALY的成本效果阈值。
  • 概率敏感性(蒙特卡洛)分析显示MVD在70%的模型迭代中具有成本效果。
  • 当支付意愿阈值低于每QALY 12,000美元时,GKRS更受青睐。

核心结论

  • 在医学上适合任一种手术的患者中,作者发现MVD是治疗三叉神经痛最具成本效果的方式,主要因为其报告的耐久性更佳。
  • 在敏感性分析中,MVD在广泛的模型输入值范围内仍是最具成本效果的策略。

研究设计与样本

  • 研究建立美国卫生体系Markov成本效果模型,从卫生体系角度、在患者终生时间跨度内计入MVD与GKRS治疗三叉神经痛的全部相关成本。
  • 基础病例采用既往研究数据、本中心GKRS经验以及当前对接受MVD患者的资料分析进行估计。
  • 模型输入(包括医疗成本、生存和效用估计)取自文献;死亡数据采用国家登记库中按年龄、性别和种族特异的死亡率。
  • 成本研究包括MVD、GKRS、两种手术并发症的治疗以及患者终生用药的费用。
  • 研究进行了多重单因素、双因素和概率敏感性分析,以确认模型假设与结果的稳健性。

主要发现

  • 基础病例中,MVD相比GKRS的ICER为每QALY 12,154美元。
  • 概率敏感性(蒙特卡洛)分析显示,MVD在70%的模型迭代中具有成本效果。
  • 当支付意愿阈值低于每QALY 12,000美元时,GKRS更受青睐。

关键数值与推荐

  • 成本效果以ICER定义,阈值为每获得1个QALY 50,000美元。
  • 基础病例MVD相比GKRS的ICER为每QALY 12,154美元。
  • 概率敏感性分析中MVD在70%的模型迭代中具有成本效果。
  • 支付意愿阈值低于每QALY 12,000美元时GKRS更受青睐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Both microvascular decompression (MVD) and Gamma Knife radiosurgery (GKRS) are time-tested treatment modalities for trigeminal neuralgia (TN). There is little evidence in the literature studying these modalities head to head in a cost-effectiveness comparison. OBJECTIVE: To evaluate the cost-effectiveness of MVD compared with GKRS for treating patients with TN. METHODS: We developed a Markov cost-effectiveness model for the U.S. health care system to account for all costs related to MVD and GKRS as treatment modalities for TN, from the health care system perspective, over a patient lifetime horizon. A base case was estimated using data from previous studies, from our own GKRS experience, and from a current data analysis of patients undergoing MVD. We derived model inputs, including health care costs, survival, and utility estimates, from the literature. We used age-specific, sex-specific, and race-specific mortality from national registries. Costs studied included those for MVD, for GKRS, for treating complications from either procedure, and for medications throughout patient lifetimes. We performed multiple 1-way, 2-way, and probabilistic sensitivity analyses to confirm the robustness of model assumptions and results. The incremental cost-effectiveness ratio (ICER), with a threshold of $50,000 per quality-adjusted life-year (QALY) gained, defined cost-effectiveness. RESULTS: The base case had an ICER of $12,154 per QALY for MVD compared with GKRS. Probabilistic sensitivity (Monte Carlo) analysis showed that MVD was cost-effective in 70% of model iterations. GKRS was favored when the willingness to pay threshold was <$12,000 per QALY gained. CONCLUSIONS: In patients medically eligible for either procedure, we found MVD to be the most cost-effective modality to treat TN, primarily because of its reported greater durability. MVD remained the most cost-effective strategy across a broad range of model input values in sensitivity analyses.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Gandhoke GS, Smith KJ, Niranjan A, et al. Comparing Microvascular Decompression with Gamma Knife Radiosurgery for Trigeminal Neuralgia. A Cost-Effectiveness Analysis. World Neurosurg. 2019. PMID: 30660885. doi:10.1016/j.wneu.2018.12.204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。